# Vaccine response in aging

Vaccines work less well as you age, and several immune changes pile up to cause it. You have fewer fresh (naive) T and B cells, weaker germinal-center reactions, shorter-lived antibody factories (plasma cells), and a jumpier innate immune system. Together these lower how strong, precise, and lasting your vaccine protection is. So vaccines for older adults are often reformulated to push harder. High-dose or adjuvanted flu shots (like Fluzone High-Dose, or Fluad with the MF59 adjuvant) raise protection rates well above standard shots in people over 65. The shingles vaccine Shingrix, which uses the AS01B adjuvant to drive a strong T-cell and antibody response, is about 90 to 97% effective depending on age (around 91% in adults 70+, from the pooled ZOE-50/ZOE-70 analysis). Compare that to roughly 50% for the older live Zostavax, which the US dropped in 2020. It is a clear example of how clever adjuvants can partly make up for age-related immune decline (immunosenescence).

## Sources

- Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. (2018). Vaccination in the elderly: the challenge of immune changes with aging. Seminars in Immunology. https://doi.org/10.1016/j.smim.2018.10.010
- Gustafson CE, Kim C, Weyand CM, Goronzy JJ. (2020). Influence of Immune Aging on Vaccine Responses. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2020.03.017

---

_Canonical: https://longevity-switzerland.com/en/glossary/vaccine-response-aging · Part of Longevity Cities · Updated 2026-06-22_